Challenges and opportunities in rare cancer research in China

No abstract is available for this paper.

• Publication year

  2023

• Venue

  Science China Life Sciences

• Publication date

  2023-11-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11427-023-2422-xPMID 38036799
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022

  2023cited by this paper
• Immunotherapies in rare cancers

  2023cited by this paper
• Clinical characteristics and outcomes of gastrointestinal stromal tumor patients receiving surgery with or without TKI therapy: a retrospective real-world study

  2023cited by this paper
• From patterns to patients: Advances in clinical machine learning for cancer diagnosis, prognosis, and treatment.

  2023cited by this paper
• Reversing the negative effect of adenosine A1 receptor-targeted immunometabolism modulation on melanoma by a co-delivery nanomedicine for self-activation of anti-PD-L1 DNAzyme

  2023cited by this paper
• Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations

  2022cited by this paper
• Gene editing and its applications in biomedicine

  2022cited by this paper
• Single cell characterization of the cellular landscape of acral melanoma identifies novel targets for immunotherapy.

  2022cited by this paper
• Cancer statistics in Chinese older people, 2022: current burden, time trends, and comparisons with the US, Japan, and the Republic of Korea

  2022cited by this paper
• Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia

  2022cited by this paper
• Chordoma: To know means to recognize.

  2022cited by this paper
• Safety, pharmacokinetics (PK), and clinical efficacy of ICP-723, a highly selective next-generation pan-TRK inhibitor, in patients with solid tumor.

  2022influential reference
• Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma

  2021cited by this paper
• Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

  2021cited by this paper
• Molecular Pathogenesis of Gastrointestinal Stromal Tumor: A Paradigm for Personalized Medicine.

  2021cited by this paper
• Single-cell RNA sequencing reveals spatiotemporal heterogeneity and malignant progression in pancreatic neuroendocrine tumor

  2021cited by this paper
• Trends in kinase drug discovery: targets, indications and inhibitor design

  2021cited by this paper
• Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

  2021cited by this paper
• Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility Study

  2021cited by this paper
• Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions

  2021cited by this paper
• Orphan drug designation and development in Japan: 25 years of experience and assessment

  2021cited by this paper
• Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma

  2021cited by this paper
• Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study.

  2020influential reference
• Burden of melanoma in China, 1990–2017: Findings from the 2017 global burden of disease study

  2020influential reference
• CASZ1 induces skeletal muscle and rhabdomyosarcoma differentiation through a feed-forward loop with MYOD and MYOG

  2020influential reference
• MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial

  2020cited by this paper
• A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma

  2020cited by this paper
• ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.

  2020influential reference
• Rationale of the rare cancer list: a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU)

  2020cited by this paper
• Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine

  2020influential reference
• Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction

  2020cited by this paper
• The current status of and prospects in research regarding gastrointestinal stromal tumors in China

  2020cited by this paper
• Comprehensive Genomic Profiling of Rare Tumors: Routes to Targeted Therapies

  2020influential reference
• Anti-PD1 checkpoint inhibitor therapy in acral melanoma: A multicentre study of 193 Japanese patients.

  2020cited by this paper
• Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.

  2020cited by this paper
• Global burden of oesophageal and gastric cancer by histology and subsite in 2018

  2020influential reference
• Adaptive T cell immunotherapy in cancer

  2020cited by this paper
• Rare cancers in Japan: definition, clinical features and future perspectives.

  2020cited by this paper
• Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.

  2020cited by this paper
• Basic research in childhood cancer: Progress and future directions in China.

  2020cited by this paper
• Pulmonary sarcomatoid carcinoma: progress, treatment and expectations

  2020cited by this paper
• BET inhibitor suppresses melanoma progression via the noncanonical NF-κB/SPP1 pathway

  2020cited by this paper
• A Human Organoid Model of Aggressive Hepatoblastoma for Disease Modeling and Drug Testing

  2020cited by this paper
• Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.

  2020influential reference
• Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.

  2020influential reference
• Current status and future outlook for patient‐derived cancer models from a rare cancer research perspective

  2020cited by this paper
• An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping.

  2020cited by this paper
• Diagnostic and therapeutic advances in neuroendocrine tumours

  2020influential reference
• Two well-differentiated pancreatic neuroendocrine tumor mouse models

  2019cited by this paper
• Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China

  2019influential reference
• Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

  2019cited by this paper
• Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can Brown do for you?

  2019cited by this paper
• Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine

  2019cited by this paper
• Preclinical rare cancer research to inform clinical trial design

  2019cited by this paper
• Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

  2018cited by this paper
• Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor.

  2018cited by this paper
• The first prospective trial for von Hippel-Lindau disease: pazopanib.

  2018cited by this paper
• Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma

  2018cited by this paper
• Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors

  2018cited by this paper
• Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

  2018cited by this paper
• Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study.

  2017influential reference
• The global burden of melanoma: results from the Global Burden of Disease Study 2015

  2017influential reference
• The burden of rare cancers in the United States

  2017influential reference
• Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

  2017influential reference
• Whole-genome landscape of pancreatic neuroendocrine tumours

  2017cited by this paper
• MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases

  2017influential reference
• Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs

  2016cited by this paper
• Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome.

  2016cited by this paper
• Rare cancers: a sea of opportunity.

  2016cited by this paper
• Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.

  2016cited by this paper
• Research methods to change clinical practice for patients with rare cancers.

  2016cited by this paper
• Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines.

  2015cited by this paper
• Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

  2015cited by this paper
• Histopathological Diagnostic Discrepancies in Soft Tissue Tumours Referred to a Specialist Centre: Reassessment in the Era of Ancillary Molecular Diagnosis

  2014influential reference
• Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.

  2013cited by this paper
• Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions.

  2012cited by this paper
• Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions.

  2012cited by this paper
• Everolimus for Advanced Pancreatic Neuroendocrine Tumors

  2012influential reference
• Everolimus for advanced pancreatic neuroendocrine tumors.

  2011cited by this paper
• DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors

  2011cited by this paper
• Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

  2011cited by this paper
• Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases

  2011influential reference
• The Occurrence of Rare Cancers in U.S. Adults, 1995–2004

  2010influential reference
• HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing

  2001cited by this paper
• The National Cancer Data Base report on cutaneous and noncutaneous melanoma

  1998influential reference
• A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma

  1986cited by this paper
• Percivall Pott and cancer scroti.

  1975cited by this paper
• Percivall Pott and cancer scroti.

  1975cited by this paper
• Mutation and cancer: statistical study of retinoblastoma.

  1971cited by this paper

• PRR11 as a newly identified oncogenic driver in retinoblastoma.

  2026cites this paper
• The bibliometric analysis of research on traditional Chinese medicine regulating gut microbiota for cancer treatment from 2014 to 2024

  2025cites this paper
• Establishing a High-quality Biomedical Resource for Rare Diseases：Insights from Pediatric Medulloblastoma

  2025cites this paper
• Multi-omics technologies and analyses provide the biological insights and therapeutic strategies for rare tumors

  2024cites this paper
• Early-onset and later-onset cancer: trends, risk factors, and prevention in Northern China

  2024cites this paper
• circTP63-N suppresses the proliferation and metastasis of nasopharyngeal carcinoma via engaging with HSP90AB1 to modulate the YAP1/Hippo signaling pathway

  2024cites this paper